MRK.DE - MERCK Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed price. Currency in EUR

MERCK Kommanditgesellschaft auf Aktien

Frankfurter Strasse 250
Darmstadt 64293
49 6151 72 0

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees54,042

Key executives

NameTitlePayExercisedYear born
Dr. Stefan OschmannChairman of Exec. Board & CEO6.55MN/A1957
Dr. Marcus KuhnertCFO & Member of Exec. Board3.55MN/A1968
Dr. Kai BeckmannCEO of Performance Materials & Member of the Exec. Board3.88MN/A1965
Dr. Udit BatraCEO of Life Science & Member of Exec. Board4.24MN/A1971
Ms. Belén Garijo López M.D.CEO of Healthcare & Member of the Exec. Board5.46MN/A1960
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc.; a collaboration with Daiichi Sankyo Company, Limited and BioMed X Innovation Center; a co-development agreement with Oncolytics Biotech Inc.; a partnership with GlucoMe LTD; and collaboration agreements with Phosplatin Therapeutics LLC and Vyriad Inc. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Corporate governance

MERCK Kommanditgesellschaft auf Aktien’s ISS governance QualityScore as of 3 February 2020 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more